BeOne Medicines (BEIGF) Current Leases (2019 - 2026)

BeOne Medicines (BEIGF) has 8 years of Current Leases data on file, last reported at $20.6 million in Q1 2026.

• Current Leases for Q1 2026 came in at $20.6 million, up 12.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.6 million (up 12.46% YoY), and the FY2025 annual result was $20.7 million, up 17.76% from the prior year.
• Current Leases slipped to $20.6 million in Q1 2026 per BEIGF's latest filing, from $20.7 million in the prior quarter.
• Over five years, Current Leases peaked at $24.8 million in Q2 2022 and troughed at $15.7 million in Q3 2025.
• A 5-year average of $20.8 million and a median of $20.7 million in 2025 frame the typical range for Current Leases.
• The sharpest annual moves came in 2022 and 2024: Current Leases soared 63.61% in 2022, then declined 24.89% in 2024.
• A 5-year view of Current Leases shows it stood at $24.0 million in 2022, then fell by 8.7% to $22.0 million in 2023, then fell by 19.93% to $17.6 million in 2024, then climbed by 17.76% to $20.7 million in 2025, then decreased by 0.55% to $20.6 million in 2026.
• Business Quant data shows BEIGF's Current Leases at $20.6 million in Q1 2026, $20.7 million in Q4 2025, and $15.7 million in Q3 2025.